Sign Out
Pregnancy: Studies in animals showed no evidence of teratogenic effects associated with lanreotide during organogenesis.
The number of pregnancies exposed to lanreotide is very limited. Therefore, lanreotide should be administered to pregnant women only if clearly needed.
Breast-feeding: It is not known whether this drug is excreted in human milk.
Because many drugs are excreted in human milk, caution should be exercised when lanreotide is administered during lactation.
Fertility: Reduced fertility was observed in female rats due to the inhibition of GH secretion at doses in excess of those achieved in humans at therapeutic doses.
